Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Motor Activity 3 Prostatic Neoplasms 2 Esophageal Neoplasms 2 Stomach Neoplasms 1 Pediatric Brain Tumor 1 Lupus Erythematosus, Systemic 1 Lung Neoplasms 1 Hodgkin Disease 1 Gastrointestinal Neoplasms 1 Disease 1 Colorectal Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 90 Carboplatin 78 Specimen Handling 76 Magnetic Resonance Spectroscopy 63 Pemetrexed 60 Cisplatin 47 durvalumab 44 Paclitaxel 38 Nivolumab 34 atezolizumab 32 Radiosurgery 30 osimertinib 29 Radiotherapy 29 Biopsy 26 Blood Specimen Collection 25 Gemcitabine 24 Docetaxel 24 Immunoglobulin G 23 Disulfides 22 Standard of Care 21 Drug Therapy 21 Etoposide 19 Taxes 18 Practice Guidelines as Topic 18 Radiation 17 Educational Status 16 130-nm albumin-bound paclitaxel 15 X-Rays 14 Surveys and Questionnaires 14 Bevacizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × High-Intensity Interval Training × 1 year × Clear all

NCT06026111 2026-04-14

ENHANCE

Dana-Farber Cancer Institute

Phase NA Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡